Bone Abstracts

Objectives: A role for glucose-dependent insulinotropic polypeptide (GIP) in controlling bone mass and strength has previously been reported. However, the rapid degradation of GIP in the bloodstream by the dipeptidyl peptidase-4 enzyme precludes therapeutic use. To circumvent this problem, a series of N-terminally modified GIP agonists have been developed. The aim of the present study was to investigate the effects of 28-day treatment with N-AcGIP on bone microarchitecture and...

Objectives: Glucagon-like peptide 1 is secreted by intestinal L-cells into the blood supply in response to nutrients in the intestine. Although osteoblasts express the GLP-1 receptor (GLP-1R), the main action of the GLP-1/GLP-1R pathway in bone physiology and bone quality is unknown. The aim of the present study was to investigate bone strength and quality in a mouse model of GLP-1R deficiency.Materials/methods: Eight 16 weeks-old GLP-1R knock-out male m...

Objectives: Glucose-dependent insulinotropic polypeptide (GIP) is secreted by intestinal K-cells into the blood supply in response to nutrient ingestion and absorption. Although osteoblasts and osteoclasts express the GIP receptor (GIPR), the main action of the GIP/GIPR pathway in bone physiology and bone quality is unknown. The aim of the present study was to investigate bone quality in a mouse model of GIPR deficiency.Materials/methods: Eleven 16 weeks...

Objectives: A role for the gut hormones glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) in controlling bone mass and strength has previously been reported. However, lack of one gut hormone is compensated by an elevated sensitivity to the other in single receptor knockout mice. As such the exact role of GIP and GLP-1 in bone is unclear. The aims of the present study were to assess bone mass and strength in mice with functional deletion of ...